Showing results (201-210 of 283) with videos related to
Sort By:
Pageof 29
Blood|May 1, 1988
Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpuraE Oksenhendler, P Bierling, Y Brossard, et al.Anti-Cancer Drugs|March 24, 1998
A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant diseaseT P Miller, E M Chase, R Dorr, et al.The Journal of Pharmacology and Experimental Therapeutics|October 17, 2001
cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathwaysG S Watts, B W Futscher, R Isett, et al.Journal of Pharmaceutical Sciences|May 1, 1978
Hydrolysis and protein binding of melphalanS Y Chang, D S Alberts, D Farquhar, et al.Cancer Research|December 1, 1979
Development of an agar-methyl cellulose clonogenic assay for cells in transitional cell carcinoma of the human bladderR N Buick, T H Stanisic, S E Fry, et al.Cancer Chemotherapy and Pharmacology|January 1, 1981
Pharmacologic studies of anticancer drugs with the human tumor stem cell assayD S Alberts, S E Salmon, H S Chen, et al.Acta Cytologica|November 1, 1978
Discrimination between human T and B lymphocytes by computer analysis of digitized data from scanning microphotometry. II. Discrimination and automated classificationP H Bartels, Y P Chen, B G Durie, et al.Cancer Treatment Reports|December 1, 1986
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in manW Scheithauer, G M Clark, S E Salmon, et al.The New England Journal of Medicine|June 15, 1978
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugsS E Salmon, A W Hamburger, B Soehnlen, et al.Journal of the National Cancer Institute|August 19, 1992
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitroE M Hersh, C R Gschwind, C W Taylor, et al.Pageof 29